BackSCIENCE_HEALTH
AIIMS-led trial finds low-cost digoxin may improve outcomes in rheumatic heart disease
A large AIIMS-led randomized trial suggests that digoxin, a low-cost heart medication, may reduce the risk of death or worsening heart failure in patients with symptomatic rheumatic heart disease. The study enrolled 1,769 adults across 12 Indian hospitals and was published in JAMA on May 10, 2026.
Why It Matters
If confirmed, digoxin could offer an affordable strategy to reduce heart failure progression in countries with limited access to hospital care.
Timeline
4 Events
News article reporting trial findings published
May 11, 2026
A news article summarizing the AIIMS-led trial findings and key results was published on May 11, 2026.
Study results published in JAMA
May 10, 2026
The randomized trial Digoxin in Patients With Symptomatic Rheumatic Heart Disease: A Randomized Clinical Trial was published in JAMA on May 10, 2026, reporting that digoxin reduced the risk of the composite outcome of all-cause death or new-onset/worsening heart failure with relatively low toxicity.
Enrollment ends for AIIMS-led digoxin study
August 2024
Enrollment across all sites was completed in August 2024.
Trial enrollment begins for AIIMS-led digoxin study
February 2022
Enrollment of 1,769 adults with symptomatic rheumatic heart disease across 12 tertiary care hospitals in India began in February 2022.